Recent advance in the study of novel anti-tumor targets and drugs--aurora kinase and Pin1.
- Author:
Xiao-guang CHEN
1
;
Yi ZHANG
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. chxg@imm.ac.cn
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Apoptosis;
drug effects;
Aurora Kinases;
Humans;
NIMA-Interacting Peptidylprolyl Isomerase;
Naphthoquinones;
pharmacology;
Neoplasms;
metabolism;
pathology;
Peptidylprolyl Isomerase;
antagonists & inhibitors;
metabolism;
Piperazines;
pharmacology;
Protein-Serine-Threonine Kinases;
antagonists & inhibitors;
metabolism
- From:
Acta Pharmaceutica Sinica
2009;44(3):264-269
- CountryChina
- Language:Chinese
-
Abstract:
Malignant tumor, one of the most refractory diseases, plays a threaten role in human health, the therapy and research on malignant tumor have taken a long way to go. The anti-tumor drugs which are the essential therapy strategies upgrade with the development of new anti-tumor targets and the research on tumor pathogenesis. Aurora kinase and Pin1, the novel anti-tumor targets, maintain the important relationship with tumor. Many new compounds designed on these targets have excellent anti-tumor effects and also enter into phase I or phase II clinical trial.
